2-[4-7-Chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIβ, up-regulates Topo II α and enhances Topo II α-mediated cytotoxicity

Molecular Cancer Therapeutics

Volumn 1, Issue 14, 2002, Pages 1321-1326

  Mensah Osman, Edith J ^a   Al Katib, Ayad M ^a   Wu, Hai Young ^b   Osman, Nadir I ^a   Mohammad, Ramzi M ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; ENZYME INHIBITOR; ETOPOSIDE; ISOPROTEIN; QUINOXALINE DERIVATIVE; TUMOR ANTIGEN; XK 469;

ARTICLE; BLOOD; CANCER TRANSPLANTATION; CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CONFOCAL MICROSCOPY; CULTURE MEDIUM; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; TIME; UPREGULATION; WALDENSTROEM MACROGLOBULINEMIA; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CULTURE MEDIA, SERUM-FREE; DNA; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; PROTEIN ISOFORMS; QUINOXALINES; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION; WALDENSTROM MACROGLOBULINEMIA;

EID: 0038380365     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bender, J. C. Treatment options for indolent lymphomas. The Fellow Reporter, ASH, 42nd Annual Meeting, 6: 55-58, 2001.
2. Bergsagel, D. E. Macroglobulinemia. In: W. J. Williams, E. Beutler, A. J. Erslev, and M. A. Lichtman (eds.), Hematology, 4th ed., pp. 1141-1145. New York: McGraw-Hill Book Co., 1990.
3. Bartl, R., Frisch, B., Mahl, G., Burkhardt, R., Fateh-Moghadam, A., Pappenberger, R., Sommerfeld, W., and Hoffmann-Fezer, G. Bone marrow histology in Waldenstrom's macroglobulinemia: clinical relevance of subtype recognition. Scand. J. Haematol., 31: 359-375, 1983. (Pubitemid 13005174)
4. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
5. Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., and Timmerman, J. Immunotherapy of non-Hodgkin's lymphomas. Hematology, 221-240, 2001.
6. Cheson, B. D. New drug development in non-Hodgkin lymphomas. Curr. Oncol. Rep., 3: 250-259, 2001.
7. Topcu, Z. DNA topoisomerases as targets for anticancer drugs. J. Clin. Pharm. Ther., 26: 405-416, 2001. (Pubitemid 34205966)
8. Bauman, M. E., Holden, J. A., Brown, K. A., Harker, W. G., and Perkins, S. L. Differential immunohistochemical staining for DNA topoisomerase II α and β in human tissues and for DNA topoisomerase II β in non-Hodgkin's lymphomas. Mod. Pathol., 10: 168-175, 1997. (Pubitemid 27130453)
9. Koshiyama, M., Fujii, H., Kinezaki, M., and Yoshida, M. Correlation between Topo II α expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Res., 21: 905-910, 2001. (Pubitemid 32494188)
10. Chapuis, J. C., Keng, P. C., and Siemann, D. W. Activity of etoposide (VP-16) and tenoposide (VM-26) in exponential and plateau phase human tumor cell cultures. Anticancer Drugs, 3: 245-252, 1992.
11. Potmesil, M., Hsiang, Y. H., Liu, L. F., Bank, B., Grossberg, H., Kirschenbaum, T. J., Penziner, A., Kanganis, D., and Forlenzar, T. J. Resistance of human leukemic and normal lymphocytes to drug DNA cleavage and low levels of DNA topoisomerase II. Cancer Res., 48: 3537-3543, 1988.
12. Nitiss, J. L., and Beck, W. T. Antitopoisomerase drug action and resistance. Eur. J. Cancer, 32: 958-966, 1996.
13. Negri, C., Chiesa, R., Cerino, A., Bestagno, M., Sala, C., Zini, N., Maraldi, N. M., and Astaldi Ricotti, G. C. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp. Cell Res., 200: 452-459, 1992.
14. Austin, C., and Marsh, K. Eukaryotic DNA topoisomerase IIβ. BioEssays, 20: 215-226, 1998.
15. Potmesil, M., Hsiang, Y. H., Liu, L. F., Wu, H. Y., Traganos, F., Bank, B., and Silber, R. DNA topoisomerase II as a potential factor in drug resistance of malignancies. Natl. Cancer Inst. Monogr., 4: 105-109, 1987. (Pubitemid 17138184)
16. Beck, J., Niethammer, D., and Gekeler, V. High mdr1- and mrp-, but low topoisomerase II α-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett., 86: 135-142, 1994.
17. Whitacre, C. M., Zborowska, E., Gordon, N. H., Mackay, W., and Berger, N. A. Topetecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res., 57: 1425-1428, 1997. (Pubitemid 27175554)
18. Gao, H., Huang, K-C., Yamasaki, E. F., Chan, K. K., Chohan, L., and Robert, M. XK469 is a selective topoisomerase IIβ poison. Proc. Natl. Acad. Sci. USA, 96: 12168-12173, 1999.
19. Wang, Y., Zhou, R., Liliemark, J., Gruber, A., Lindelmalm, S., Albertioni, F., and Liliemark, E. In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia. Leuk. Res., 25: 133-140, 2001. (Pubitemid 32141116)
20. Oloumi, A., MacPhail, S. H., Johnston, P. J., Banath, J. P., and Olive, P. L. Changes in subcellular distribution of topoisomerase IIα correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res., 60: 5747-5753, 2000.
21. Mensah-Osman, E. J., Al-Katib, A. M., Dandashi, M. H., and Mohammad, R. M. 2-[4-(7-Chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIβ is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Mol. Cancer Ther., 1: 1315-1320, 2002.
22. Bjornsti, M., and Osheroff, N. DNA topoisomerase protocols: DNA topology and enzymes. Methods Mol. Biol., 95: 283-287, 1999.
23. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2: 209-214, 1991.
24. Pardee, A. B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA, 71: 1286-1290, 1974.
25. Pu, Q. Q., and Bezwoda, R. Alkylator resistance in human B lymphoid cell lines. II. Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line. Anticancer Res., 20: 2571-2580, 2000.
26. Froelich-Ammon, S. J., and Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem., 270: 21429-21432, 1995.